AccessibilityHelpAbout Us
Immuron logo

Immuron(NASDAQ) IMRN

Market Cap$14.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-82%
5 Year-62%
1 Year-2%
1 Month+78%
$1.79
-2.72%
-0.05Today
Immuron last closing stock price
MetricPriceDate
Last closeUSD 1.842026-09-08
Immuron stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+71.96%USD 1.072026-09-01
1 month+78.47%USD 1.032026-08-07
3 month+57.26%USD 1.172026-06-10
Year to date+141.31%USD 0.762025-12-31
1 year-2.13%USD 1.882025-09-08
3 year-8%USD 2.002023-09-08
5 year-62.06%USD 4.852021-05-27
Since inception-82.44%USD 10.482017-03-02

Immuron Financials at a Glance

Market Cap

$14.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$12.63M

Net Income (TTM)

-A$7.96M

EPS (TTM)

-$0.35

P/E Ratio

-5.27

Dividend

$0.00

Beta (Volatility)

0.66 (Low)

Price

$1.79

Volume

541,165.574

Open

$1.77

Previous Close

$1.84

Daily Range

$1.77 - $1.85

52-Week Range

$0.68 - $2.39

Estimated Earnings Date

Feb 19, 2027

IMRN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immuron

Immuron Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of polyclonal antibodies. With operations in Australia, the United States, and other international markets, Immuron focuses on innovative healthcare solutions.

Products and Services
  • Travelan: An OTC medicine reducing the risk of traveler's diarrhea
  • Protectyn: An immune supplement supporting digestive and liver health
  • IMM-124E: Advanced formulation of Travelan in Phase III trials
Growth Outlook
  • Recent revenue of AUD 4.1 million indicates strong market demand
  • Pipeline includes IMM-529 for recurrent Clostridium difficile infections
  • Strategic collaborations with military research institutes enhance development
Financial Highlights
  • Quarterly revenue increased to AUD 4.1 million, up from AUD 3.3 million
  • Cash and cash equivalents reached AUD 9.9 million, providing operational stability
  • Current ratio of 8.04 indicates strong liquidity position
Immuron Limited is positioned in the biotechnology sector, focusing on innovative healthcare solutions through its unique product offerings. The company has demonstrated a commitment to addressing significant health challenges, particularly in gastrointestinal health and immune support. The recent revenue growth reflects a positive market response to its products, while the ongoing clinical trials for new formulations signal potential future expansion. Strategic partnerships with reputable research institutions further enhance the company's credibility and development capabilities. Financially, Immuron maintains a robust liquidity position, which is crucial for supporting ongoing research and development efforts. Overall, Immuron Limited presents an intriguing opportunity for investors interested in the biotechnology sector.
AI Generated • Aug 19, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Steven Lydeamore, MBA

Website

www.immuron.com.au

Headquarters

Carlton, VIC 3053, AU

IMRN Financials

Key Financial Metrics (TTM)

Gross Margin

64.50%

Operating Margin

-61.39%

Net Income Margin

-49.77%

Return on Equity

-31.88%

Return on Capital

-42.08%

Return on Assets

-29.54%

Earnings Yield

-18.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.07M

Volume

541.17K

Avg. Volume

2.05M

Financials (TTM)

Gross Profit

A$8.12M

Operating Income

-A$8.97M

EBITDA

-A$9.01M

Operating Cash Flow

-A$6.41M

Capital Expenditure

-A$4.99K

Free Cash Flow

-A$6.42M

Cash & ST Invst.

A$9.02M

Total Debt

A$0.00

Immuron Performance Analysis

Immuron annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 1,214,033118.8%
20242024-06-30AUD 3,213,215164.7%
20252025-06-30AUD 4,719,28846.9%
20262026-06-30AUD 5,226,91310.8%
Immuron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-03-31-58.8%
Q42025-06-30100.0%
Q22025-12-31N/A
Q42026-06-30N/A
Immuron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.4522.9%
20242024-06-30AUD -0.8078.4%
20252025-06-30AUD -0.59-26.7%
20262026-06-30AUD -0.35-40.2%
Immuron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-03-3146.3%
Q42025-06-30-103.4%
Q22025-12-31N/A
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$3.58M

-10.4%

Gross Profit

A$2.35M

-11.4%

Gross Margin

65.78%

N/A

Market Cap

$14.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.12M

N/A

Employees

7

N/A

Net Income

-A$1.95M

+21.8%

EBITDA

-A$2.46M

+2.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$9.02M

+16.6%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$1.25M

+8.9%

Inventory

A$2.27M

+49.9%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$0.00

-100.0%

Return on Assets

-29.54%

N/A

Return on Invested Capital

-42.25%

N/A

Free Cash Flow

-A$767.38K

+80.8%

Operating Cash Flow

-A$767.06K

+80.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COCPCocrystal Pharma, Inc.
$1.24+4.66%
SNSESensei Biotherapeutics, Inc.
$13.85-22.28%
CLRBCellectar Biosciences, Inc.
$2.39-0.83%
TRAWTraws Pharma, Inc.
$0.55-1.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$146.73-0.04%
NOKNokia
$10.91+0.02%
INTCIntel
$105.46+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.57+0.00%

Questions About IMRN

What is the current price of Immuron?

Immuron is trading at $1.79 per share.

What is the 52-week range for Immuron?

Over the past 52 weeks, Immuron has traded between $0.68 and $2.39.

How much debt does Immuron have?

As of the most recent reporting period, Immuron reported total debt of A$0.00.

How much cash does Immuron have on hand?

Immuron reported A$6.25M in cash and cash equivalents in its most recent financial results.

What is Immuron’s dividend yield?

Immuron does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services